Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF

Inclusion Criteria: * Patients with stage IV renal cancer who have not received prior chemotherapy or biological therapy * Patients who are to undergo debulking nephrectomy for independent clinical indications or patients with other sites of accessible disease * Tumor tissue should be at least 2.0cm in longest dimension * Patients should meet prognostic criteria for intermediate or favorable risk disease as defined by Motzer criteria * Measurable metastatic disease as defined by a lesion of at least 1cm outside the lesion used for vaccine generation and exclusive of bony metastases * ECOG Performance Status of 0-2 with greater than six week life expectancy * 18 years of age or older * Lab results within range outlined in protocol Exclusion Criteria: * Patients who have received prior chemotherapy * Clinical evidence of CNS disease. Patients with a history of treated brain metastasis must be stable with no evidence of disease for 3 months * HIV positive * Serious intercurrent illness such as infection requiring IV antibiotics, or significant cardiac disease characterized by significant arrhythmia, unstable ischemic coronary disease or congestive heart failure * Pregnant of lactating women * History of clinically significant venous thromboembolism